OverviewSuggest Edit

Travere Therapeutics is a biopharmaceutical company that focuses on the development, acquisition, and commercialization of therapies for the treatment of serious or rare diseases. Its marketed products include Chenodal, Cholbam, and Thiola. The Company also has a number of product candidates to treat various serious diseases.
TypePublic
Founded2011
HQSan Diego, CA, US
Websitetravere.com
Employee Ratings4.3

Latest Updates

Employees (est.) (Sept 2021)239(+9%)
Job Openings89
Revenue (FY, 2020)$198.3 M(+14%)
Share Price (Nov 2021)$29.8
Cybersecurity ratingAMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Travere Therapeutics

Eric Dube

Eric Dube

President and Chief Executive Officer
Laura Clague

Laura Clague

Chief Financial Officer
Peter Heerma

Peter Heerma

Chief Commercial Officer
Noah L. Rosenberg

Noah L. Rosenberg

Chief Medical Officer
William Rote

William Rote

Senior Vice President of Research & Development
Elizabeth Reed

Elizabeth Reed

Senior Vice President, General Counsel, Corporate Secretary
Show more

Travere Therapeutics Office Locations

Travere Therapeutics has offices in San Diego and Dublin
San Diego, CA, US (HQ)
3721 Valley Centre Dr #200san
Dublin, IE
2nd Floor, Palmerston House, Fenian St
Show all (2)

Travere Therapeutics Financials and Metrics

Travere Therapeutics Revenue

Travere Therapeutics's revenue was reported to be $198.32 m in FY, 2020
USD

Revenue (Q1, 2021)

47.4m

Gross profit (Q1, 2021)

45.8m

Gross profit margin (Q1, 2021), %

96.5%

Net income (Q1, 2021)

(53.9m)

EBIT (Q1, 2021)

(47.5m)

Market capitalization (12-Nov-2021)

1.8b

Closing stock price (12-Nov-2021)

29.8

Cash (31-Mar-2021)

148.2m

EV

1.9b
Travere Therapeutics's current market capitalization is $1.8 b.
Annual
USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

28.2m99.9m133.6m154.9m164.2m175.3m198.3m

Revenue growth, %

254%34%

Cost of goods sold

571.0k2.2m4.6m3.6m5.5m5.2m6.1m

Gross profit

27.6m97.7m129.0m151.3m158.7m170.1m192.2m
Quarterly
USDQ2, 2012Q3, 2012Q2, 2013Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Revenue

27.9k5.7m8.3m17.4m24.1m29.0m33.3m33.9m33.6m38.8m40.3m38.4m41.3m40.7m39.6m44.7m44.4m47.8m48.4m51.1m47.4m

Cost of goods sold

900.01.2m197.4k274.4k637.0k513.0k757.0k1.0m1.6m709.0k797.0k925.0k1.6m1.2m1.1m1.0m979.0k1.5m1.5m1.2m1.6m

Gross profit

27.0k4.5m8.2m17.1m23.4m28.3m32.3m32.4m32.9m38.0m39.4m36.8m40.2m39.6m38.6m43.7m42.9m46.9m50.0m45.8m

Gross profit Margin, %

97%79%98%98%97%97%97%95%98%98%98%96%97%97%97%98%97%97%98%97%
Annual
USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

11.4k6.0m18.2m37.8m41.0m99.4m102.9m62.4m84.8m

Accounts Receivable

8.0m12.5m18.5m13.9m14.5m18.0m

Prepaid Expenses

1.4m813.4k2.4m3.1m2.3m5.0m8.1m

Inventories

800.5k2.5m2.8m5.4m5.6m6.1m7.6m
Show all financial metrics

Travere Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

91/100

SecurityScorecard logo

Travere Therapeutics Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

Travere Therapeutics Online and Social Media Presence

Embed Graph

Travere Therapeutics News and Updates

Travere Therapeutics Announces Transition of Chief Medical Officer

SAN DIEGO, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that its chief medical officer, Noah Rosenberg, M.D., has chosen to transition for personal reasons to an executive advisor role at the end of 2021. Dr. Rosenberg is expected to serve as an advis…

Retrophin Completes Acquisition of Orphan Technologies

Addition of OT-58 strengthens pipeline of potential first-in-class therapies targeting rare diseases Addition of OT-58 strengthens pipeline of potential first-in-class therapies targeting rare diseases

Retrophin, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Oct. 14, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (Nasdaq: RTRX) today announced that on October 10, 2020, the Compensation Committee of its Board of Directors granted inducement equity grants covering an aggregate of 58,750 shares of its common stock to four new employees, consisting o…

Retrophin Announces Enrollment of First 280 Patients in Pivotal Phase 3 PROTECT Study of Sparsentan in IgA Nephropathy

Topline data from 36-week proteinuria endpoint anticipated in third quarter of 2021 Topline data from 36-week proteinuria endpoint anticipated in third quarter of 2021

Retrophin to Present at the BMO 2020 Prescriptions for Success Healthcare Conference

SAN DIEGO, June 19, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that Eric Dube, Ph.D., chief executive officer, will present at the BMO 2020 Prescriptions for Success Healthcare Conference on Tuesday, June 23, 2020 at 10:00 a.m. ET.

Retrophin Announces Pricing of Public Offering of Common Stock

SAN DIEGO, June 08, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (Nasdaq: RTRX) today announced the pricing of an underwritten public offering of 6,500,000 shares of its common stock at a price to the public of $15.50 per share. All of the shares are being sold by Retrophin. The gross proceeds from th…
Show more

Travere Therapeutics Blogs

Travere Therapeutics and Vifor Pharma Announce Licensing Agreement for the Commercialization of Sparsentan in Europe, Australia and New Zealand

SAN DIEGO and ST GALLEN , Switzerland , Sept. 15, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) and Vifor Pharma today announced the companies have entered into a joint collaboration and licensing agreement for the commercialization of sparsentan in Europe , Australia and New Ze…

Travere Therapeutics Appoints Ruth Williams-Brinkley to its Board of Directors

SAN DIEGO , Sept. 14, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced the appointment of Ruth Williams-Brinkley to the Company’s Board of Directors, effective immediately. Ms. Williams-Brinkley brings to Travere more than 35 years of executive leadership in care de…

Travere Announces Successful Outcome from Type A Meeting with U.S. FDA for Sparsentan in Focal Segmental Glomerulosclerosis

SAN DIEGO, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced a successful outcome from the Company’s Type A meeting with the U.S. Food and Drug Administration (FDA) in which alignment was reached on the Company’s plan to submit additional estimated glomerul…

Travere Therapeutics Reports Second Quarter 2021 Financial Results

Travere Therapeutics Reports Second Quarter 2021 Financial Results Ephraim.DeGuia… Thu, 07/29/2021 - 16:02 Travere Therapeutics Reports Second Quarter 2021 Financial Results Jul 29, 2021 This release is a backfill from a News Wire Earnings Company …

Travere Therapeutics to Report Second Quarter 2021 Financial Results

SAN DIEGO , July 22, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report second quarter 2021 financial results on Thursday, July 29, 2021 after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Content Import Wed, 07/14/2021 - 16:31 Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Jul 14, 2021 This release is a backfill from a News Wire …
Show more

Travere Therapeutics Frequently Asked Questions

  • When was Travere Therapeutics founded?

    Travere Therapeutics was founded in 2011.

  • Who are Travere Therapeutics key executives?

    Travere Therapeutics's key executives are Eric Dube, Laura Clague and Peter Heerma.

  • How many employees does Travere Therapeutics have?

    Travere Therapeutics has 239 employees.

  • What is Travere Therapeutics revenue?

    Latest Travere Therapeutics annual revenue is $198.3 m.

  • What is Travere Therapeutics revenue per employee?

    Latest Travere Therapeutics revenue per employee is $829.8 k.

  • Who are Travere Therapeutics competitors?

    Competitors of Travere Therapeutics include Genexine, JCR Pharmaceuticals and Bath ASU.

  • Where is Travere Therapeutics headquarters?

    Travere Therapeutics headquarters is located at 3721 Valley Centre Dr #200san, San Diego.

  • Where are Travere Therapeutics offices?

    Travere Therapeutics has offices in San Diego and Dublin.

  • How many offices does Travere Therapeutics have?

    Travere Therapeutics has 2 offices.